BRCA1 and BRCA2 mutations in Iranian breast cancer patients: A systematic review
Hossein Neamatzadeh1, Seyed Mostafa Shiryazdi2, Seyed Mahdi Kalantar1
1Department of Medical Genetics, Hematology, Oncology and Genetics Research Center, Shahid Sadoughi Training Hospital, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
Background:
BRCA1/2 genes mutation prevalence varies among ethnic groups and may be influenced by founder mutations. Understanding BRCA1/2 genes mutations is important for reducing breast cancer (BC) incidence, accurate risk assessment and counseling. This systematic review of the literature was conducted to addressing BRCA1/2 mutations in Iranian BC patients.
Materials And Methods:
A search for relevant articles was run on before January 2014 using MedLine, PubMed, Science Iranian Database, Google, and Web sites related to the study topic. The key words included: BC and Iran with Genes, BRCA Genes, BRCA1 and BRCA2; "Cancer Genes," and "Iran."
Results:
Thirteen articles retrieved from this search strategy were eligible for this review. The overall BRCA1 mutation rate for Iranian female BC patients was detected 31.8% (377/1183). Although this gene mutation rate for male patients is <0.01%. Eight BRCA1 mutations (c. 4837A > G, c. 3419G > A, c. 3119G > A, c. 2612C > T, c. 3113A > G, c. 2311T > C, c. 4301T > C and c. 4308T > C in BRCA1, and one BRCA2 mutation (c. 6494G > C) were found in multiple case subjects and represent candidate founder mutations.
Conclusion:
According to these studies, there is heterogeneity in BRCA mutations in Iranian BC patients.
